دورية أكاديمية
Down syndrome and leukemia: An insight into the disease biology and current treatment options.
| العنوان: | Down syndrome and leukemia: An insight into the disease biology and current treatment options. |
|---|---|
| المؤلفون: | Barwe SP; Lisa Dean Moseley Institute for Cancer and Blood Disorders, Nemours Children's Health, Wilmington, Delaware, 19803, USA., Kolb EA; Lisa Dean Moseley Institute for Cancer and Blood Disorders, Nemours Children's Health, Wilmington, Delaware, 19803, USA., Gopalakrishnapillai A; Lisa Dean Moseley Institute for Cancer and Blood Disorders, Nemours Children's Health, Wilmington, Delaware, 19803, USA. Electronic address: anil.g@nemours.org. |
| المصدر: | Blood reviews [Blood Rev] 2024 Mar; Vol. 64, pp. 101154. Date of Electronic Publication: 2023 Nov 25. |
| نوع المنشور: | Journal Article; Review |
| اللغة: | English |
| بيانات الدورية: | Publisher: Elsevier Country of Publication: England NLM ID: 8708558 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1532-1681 (Electronic) Linking ISSN: 0268960X NLM ISO Abbreviation: Blood Rev Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: 2001- : London : Elsevier Original Publication: [Edinburgh ; New York] : Churchill Livingstone, [c1987- |
| مواضيع طبية MeSH: | Down Syndrome*/complications , Down Syndrome*/genetics , Down Syndrome*/therapy , Leukemia, Megakaryoblastic, Acute*/drug therapy , Leukemia, Megakaryoblastic, Acute*/genetics, Child ; Animals ; Humans ; GATA1 Transcription Factor/genetics ; Mutation ; Recurrence ; Biology |
| مستخلص: | Children with Down syndrome (DS) have a 10- to 20-fold greater predisposition to develop acute leukemia compared to the general population, with a skew towards myeloid leukemia (ML-DS). While ML-DS is known to be a subtype with good outcome, patients who relapse face a dismal prognosis. Acute lymphocytic leukemia in DS (DS-ALL) is considered to have poor prognosis. The relapse rate is high in DS-ALL compared to their non-DS counterparts. We have a better understanding about the mutational spectrum of DS leukemia. Studies using animal, embryonic stem cell- and induced pluripotent stem cell-based models have shed light on the mechanism by which these mutations contribute to disease initiation and progression. In this review, we list the currently available treatment strategies for DS-leukemias along with their outcome with emphasis on challenges with chemotherapy-related toxicities in children with DS. We focus on the mechanisms of initiation and progression of leukemia in children with DS and highlight the novel molecular targets with greater success in preclinical trials that have the potential to progress to the clinic. Competing Interests: Declaration of Competing Interest None. (Copyright © 2023 Elsevier Ltd. All rights reserved.) |
| فهرسة مساهمة: | Keywords: Acute leukemia; CRLF2; Cohesin; DS-ALL; Down syndrome; GATA1; GATA1s; ML-DS |
| المشرفين على المادة: | 0 (GATA1 Transcription Factor) |
| تواريخ الأحداث: | Date Created: 20231128 Date Completed: 20240312 Latest Revision: 20240312 |
| رمز التحديث: | 20240312 |
| DOI: | 10.1016/j.blre.2023.101154 |
| PMID: | 38016838 |
| قاعدة البيانات: | MEDLINE |
Full Text via ClinicalKey 
Full Text Finder | تدمد: | 1532-1681 |
|---|---|
| DOI: | 10.1016/j.blre.2023.101154 |